NCT04722471View on ClinicalTrials.gov

Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.

CompletedOBSERVATIONAL

Enrollment

347

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

March 3, 2021

Study Completion Date

March 17, 2021

Conditions

Luteal Phase Defect

Interventions

DRUG

Vaginally administered progesterone

The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)

Trial Locations (1)

03016

Instituto Bernabeu, Alicante